Flecainide: Current status and perspectives in arrhythmia management.

Article Details

Citation
Copy to clipboard

Andrikopoulos GK, Pastromas S, Tzeis S

Flecainide: Current status and perspectives in arrhythmia management.

World J Cardiol. 2015 Feb 26;7(2):76-85. doi: 10.4330/wjc.v7.i2.76.

PubMed ID
25717355 [ View in PubMed
]
Abstract

Flecainide acetate is a class IC antiarrhythmic agent and its clinical efficacy has been confirmed by the results of several clinical trials. Nowadays, flecainide is recommended as one of the first line therapies for pharmacological conversion as well as maintenance of sinus rhythm in patients with atrial fibrillation and/or supraventricular tachycardias. Based on the Cardiac Arrhythmia Suppression Trial study results, flecainide is not recommended in patients with structural heart disease due to high proarrhythmic risk. Recent data support the role of flecainide in preventing ventricular tachyarrhythmias in patients with catecholaminergic polymorphic ventricular tachycardia associated both with ryanodine receptor and calsequestrin mutations. We herein review the current clinical data related to flecainide use in clinical practice and some concerns about its role in the management of patients with coronary artery disease.

DrugBank Data that Cites this Article

Drugs
Drug Enzymes
DrugEnzymeKindOrganismPharmacological ActionActions
FlecainideCytochrome P450 1A2ProteinHumans
Unknown
Substrate
Details
FlecainideCytochrome P450 2D6ProteinHumans
Unknown
Substrate
Inhibitor
Details
Drug Reactions
Reaction
Flecainide
DB01195
    Meta-O-dealkylated flecainide
    DBMET00905
    		Details
    Flecainide
    DB01195
      Meta-o-dealkylated lactam
      DBMET00906
      		Details
      Drug Interactions
      DrugsInteraction
      Integrate drug-drug
      interactions in your software
      Flecainide
      Tipranavir      		The serum concentration of Flecainide can be increased when it is combined with Tipranavir.